11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Western General Hospital · Edinburgh Cancer Research · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,035
total citations
- FWCI
- 44.34
- Percentile
- 100%
- References
- 22
Citations per year
Authors
18- DCDavid CameronCorresponding
Western General Hospital, Edinburgh Cancer Research
- MPMartine Piccart
Université Libre de Bruxelles
- RDRichard D. Gelber
Université Libre de Bruxelles, Harvard University, Dana-Farber Cancer Institute, Frontier Science & Technology Research Foundation, Institut Jules Bordet
- MPMarion Procter
Frontier Agriculture (United Kingdom)
- AGAron Goldhirsch
European Institute of Oncology
Topics & keywords
Topics
Keywords
- Trastuzumab
- Adjuvant
- Medicine
- Oncology
- Internal medicine
- Adjuvant chemotherapy
- Breast cancer
- Chemotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.